Phenytoin
Dilantin, Diphenylan, Phenytex (phenytoin) is a small molecule pharmaceutical. Phenytoin was first approved as Dilantin-125 on 1982-01-01. It is used to treat epilepsy, status epilepticus, temporal lobe epilepsy, and tonic-clonic epilepsy in the USA. The pharmaceutical is active against sodium channel protein type 2 subunit alpha.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Dilantin (generic drugs available since 1982-01-01, discontinued: Dilantin, Diphenylan, Phenytex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| status epilepticus | EFO_0008526 | D013226 | G41 |
| temporal lobe epilepsy | EFO_0000773 | D004833 | — |
| tonic-clonic epilepsy | EFO_0007262 | D004830 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 5 | 1 | 1 | 2 | 2 | 11 |
| Seizures | D012640 | G40.4 | — | — | — | 4 | — | 4 | |
| Traumatic brain injuries | D000070642 | S06 | 1 | — | 1 | 1 | — | 3 | |
| Depression | D003863 | F33.9 | — | — | 1 | 1 | — | 2 | |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | 1 | 1 | 2 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | 1 | — | 1 | |
| Pneumococcal meningitis | D008586 | EFO_1001114 | G00.1 | — | — | — | 1 | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | 1 | — | 1 |
| Drug resistant epilepsy | D000069279 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | — | 1 | — | 3 | 12 | ||
| Post-traumatic epilepsy | D004834 | — | — | 2 | — | — | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | 1 | — | — | 1 |
| Dementia | D003704 | F03 | — | — | 1 | — | — | 1 | |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Craniocerebral trauma | D006259 | S00 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 2 | 2 | — | — | — | 2 | |
| Lymphoma | D008223 | C85.9 | 2 | 2 | — | — | — | 2 | |
| Optic neuritis | D009902 | EFO_0007405 | H46 | — | 2 | — | — | — | 2 |
| Nodding syndrome | D064128 | — | 1 | — | — | — | 1 | ||
| Neuroblastoma | D009447 | EFO_0000621 | 1 | 1 | — | — | — | 1 | |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 1 | — | — | — | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | 1 | 1 | — | — | — | 1 | |
| Precancerous conditions | D011230 | 1 | 1 | — | — | — | 1 | ||
| Plasma cell neoplasms | D054219 | 1 | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
| Wound healing | D014945 | GO_0042060 | 1 | — | — | — | — | 1 | |
| Cocaine-related disorders | D019970 | F14 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cysticercosis | D003551 | EFO_0007231 | B69 | — | — | — | — | 1 | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | 1 | 1 | ||
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | — | 1 | 1 |
| Rectal fistula | D012003 | HP_0010447 | K60.3 | — | — | — | — | 1 | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 1 | 1 |
| Pressure ulcer | D003668 | L89 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PHENYTOIN |
| INN | phenytoin |
| Description | Phenytoin is a imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5. It has a role as an anticonvulsant, a teratogenic agent, a drug allergen and a sodium channel blocker. It is functionally related to a hydantoin. |
| Classification | Small molecule |
| Drug class | antiepileptics (hydantoin derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1 |
Identifiers
| PDB | — |
| CAS-ID | 57-41-0 |
| RxCUI | 8183 |
| ChEMBL ID | CHEMBL16 |
| ChEBI ID | 8107 |
| PubChem CID | 1775 |
| DrugBank | DB00252 |
| UNII ID | 6158TKW0C5 (ChemIDplus, GSRS) |
Target
Agency Approved
SCN2A
SCN2A
Organism
Homo sapiens
Gene name
SCN2A
Gene synonyms
NAC2, SCN2A1, SCN2A2
NCBI Gene ID
Protein name
sodium channel protein type 2 subunit alpha
Protein synonyms
HBSC II, Sodium channel protein brain II subunit alpha, Sodium channel protein type II subunit alpha, sodium channel protein, brain type 2 alpha subunit, sodium channel, voltage-gated, type II, alpha 1 polypeptide, sodium channel, voltage-gated, type II, alpha 2 polypeptide, sodium channel, voltage-gated, type II, alpha subunit, voltage-gated sodium channel subtype II, Voltage-gated sodium channel subunit alpha Nav1.2, voltage-gated sodium channel type II alpha subunit
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 28,192 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,530 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more